Filtros de búsqueda

Lista de obras de Evangelos Terpos

A European consensus report on blood cell identification: terminology utilized and morphological diagnosis concordance among 28 experts from 17 countries within the European LeukemiaNet network WP10, on behalf of the ELN Morphology Faculty ⬇️

artículo científico publicado el 1 de noviembre de 2010

A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study

artículo científico publicado en 2013

A review of the venous thrombotic issues associated with multiple myeloma

artículo científico publicado en 2016

A revised international prognostic score system for Waldenström's macroglobulinemia

artículo científico publicado en 2019

Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton

scientific article published on 01 January 2007

Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenstrom macroglobulinaemia

artículo científico publicado en 2006

Activin-A is elevated in patients with thalassemia major and double heterozygous sickle cell/beta-thalassemia and correlates with markers of hemolysis and bone mineral density

scientific article published on 30 April 2019

An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when

scholarly article by Jo Caers et al published 31 August 2018 in Haematologica

An update on the use of lenalidomide for the treatment of multiple myeloma

artículo científico

Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study

artículo científico publicado en 2020

Antibody therapies for multiple myeloma

artículo científico publicado en 2020

Biology and treatment of myeloma related bone disease.

artículo científico publicado en 2017

Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group

artículo científico publicado en 2021

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group

scientific article published on 06 March 2019

Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice

artículo científico publicado en 2018

Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice

artículo científico publicado en 2018

Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.

artículo científico publicado en 2016

Cardiac and renal complications of carfilzomib in patients with multiple myeloma

artículo científico publicado en 2017

Carfilzomib for treating myeloma

Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients

scientific article published on 03 November 2020

Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations

scientific article published on 03 April 2020

Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity

artículo científico publicado en 2020

Circulating Levels of Angiogenic Cytokines in Waldenstrom’s Macroglobulinemia: Clinical Correlations

Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia

artículo científico publicado en 2018

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction

artículo científico publicado en 2020

Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.

artículo científico publicado en 2011

Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection

scientific article published on 01 July 2020

Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens

artículo científico publicado en 2013

Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis

artículo científico publicado en 2016

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents

scientific article published on 14 April 2020

Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.

artículo científico publicado en 2014

Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases

Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy

artículo científico publicado en 2015

Conservative treatment of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients

artículo científico publicado en 2014

Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates

artículo científico publicado en 2019

Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with mu

artículo científico publicado en 2020

Controversies in the use of new bone-modifying therapies in multiple myeloma

artículo científico publicado en 2020

Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia

artículo científico publicado en 2017

Current treatments for renal failure due to multiple myeloma

artículo científico

Current treatments for renal failure due to multiple myeloma

artículo científico publicado en 2016

Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration

artículo científico publicado en 2009

Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects

artículo científico publicado en 2016

Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance

scientific article published on 23 August 2020

Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma

scientific article published on 04 November 2020

Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial

artículo científico publicado en 2018

Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies

artículo científico publicado en 2018

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study

article

Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients

artículo científico publicado en 2012

Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma.

artículo científico publicado en 2017

Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma

scientific article published on 22 January 2019

Efficacy and safety of elotuzumab for the treatment of multiple myeloma

artículo científico publicado en 2017

Efficacy of Panobinostat for the Treatment of Multiple Myeloma

artículo científico publicado en 2020

Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis

artículo científico publicado en 2018

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.

artículo científico publicado en 2011

Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM

artículo científico publicado en 2018

Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma

scientific article published on 04 November 2019

Emerging antibodies for the treatment of multiple myeloma

artículo científico publicado en 2016

Emerging drugs for Waldenström's macroglobulinemia ⬇️

artículo científico publicado el 1 de marzo de 2011

Emerging treatment approaches for myeloma-related bone disease

artículo científico publicado en 2017

European Myeloma Network guidelines for the management of multiple myeloma-related complications

artículo científico publicado en 2015

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

artículo científico publicado en 2014

European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.

artículo científico publicado en 2010

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias

artículo científico publicado en 2018

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

artículo científico publicado en 2018

Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma

artículo científico publicado en 2016

Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma

scientific article published on 22 July 2020

Expression of CCL3 by Neoplastic Cells in Patients with Waldenström's Macroglobulinemia: An Immunohistochemical Study in Bone Marrow Biopsies of 67 Patients

artículo científico publicado en 2011

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma

article

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

artículo científico publicado en 2018

Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy

artículo científico publicado en 2017

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

artículo científico publicado en 2015

Glomerular expression of matrix metalloproteinases in AL-amyloidosis and association with renal function at the time of kidney biopsy

artículo científico publicado en 2015

Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis

artículo científico publicado en 2018

Helicobacter pylori infection in patients with nonalcoholic fatty liver disease.

artículo científico publicado en 2012

Hematologic Response and Stabilization of Renal Function in a Patient With Light Chain Deposition Disease After Lenalidomide Treatment: A Novel Therapeutic Approach?

article

Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens.

artículo científico publicado en 2016

Hematological findings and complications of COVID-19

artículo científico publicado en 2020

High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents

artículo científico publicado en 2009

High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients

Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents

artículo científico publicado en 2014

Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome

artículo científico publicado en 2012

Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents

scholarly article by Anna Tasidou et al published 6 May 2012 in American Journal of Hematology

Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma

artículo científico publicado en 2011

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

artículo científico publicado en 2016

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

artículo científico publicado en 2016

International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease

artículo científico publicado en 2013

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

artículo científico publicado en 2014

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

scientific article published on 01 June 2019

Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib

scientific article published on 22 July 2020

Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience

artículo científico publicado en 2015

Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment

artículo científico publicado en 2010

Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis.

artículo científico publicado en 2014

Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma

Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias

artículo científico publicado en 2011

Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period

artículo científico publicado en 2020

Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

artículo científico publicado en 2015

Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: re

artículo científico publicado en 2018

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis

artículo científico publicado en 2018

Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody

artículo científico publicado en 2019

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

scientific article published on 22 May 2020

Mechanisms of bone destruction in multiple myeloma

artículo científico publicado en 2017

Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin

scientific article published on 27 November 2018

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era.

artículo científico publicado en 2012

Multiple myeloma: Role of autologous transplantation

artículo científico publicado en 2019

Myeloma bone disease: from biology findings to treatment approaches

artículo científico publicado en 2019

Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma

artículo científico publicado en 2008

Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma

artículo científico publicado en 2015

Next generation flow cytometry for MRD detection in patients with AL amyloidosis

artículo científico publicado en 2020

No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years

scientific article published on 20 April 2011

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection

artículo científico publicado en 2020

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

artículo científico publicado en 2011

Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma

artículo científico publicado en 2013

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

artículo científico publicado en 2018

Prevention and treatment of myeloma bone disease

artículo científico

Primary failure of bortezomib in newly diagnosed multiple myeloma--understanding the magnitude, predictors, and significance

artículo científico publicado en 2016

Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis

scientific article published on 13 May 2020

Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone

artículo científico publicado en 2019

Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase

artículo científico publicado en 2009

Prognostication of the High-Risk WM Patient

artículo científico publicado en 2011

Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial

artículo científico publicado en 2010

Proteasome inhibitor therapy for Waldenström's macroglobulinemia

artículo científico publicado en 2013

Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma

artículo científico publicado en 2016

Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group

artículo científico publicado en 2020

Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

scientific article published on 01 April 2020

Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd

scientific article published on 09 March 2020

Recent Data Supporting Novel Management Strategies for Patients With Multiple Myeloma

artículo científico publicado en 2016

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

artículo científico publicado en 2020

Renal Insufficiency and Failure ⬇️

artículo científico publicado el 1 de enero de 2010

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

artículo científico publicado en 2010

Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens

artículo científico publicado en 2011

Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy

artículo científico publicado en 2017

Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause

artículo científico publicado en 2020

Response to Comment-Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology

artículo científico publicado en 2019

Response to bortezomib of a patient with scleromyxedema refractory to other therapies

article

Retreatment and Prolonged Therapy with Subcutaneous Bortezomib in Patients with Relapsed Multiple Myeloma: A Randomized, Controlled, Phase III Study

artículo científico publicado en 2017

Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents

artículo científico publicado en 2010

Rituximab-based treatments in Waldenström's macroglobulinemia

scientific article published on March 2009

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

artículo científico publicado en 2017

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement

artículo científico publicado en 2015

Role of the RANK/RANKL Pathway in Multiple Myeloma

artículo científico publicado en 2018

Sclerostin: a possible target for the management of cancer-induced bone disease

artículo científico

Screening for Gaucher disease among patients with plasma cell dyscrasias

artículo científico publicado en 2019

Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma.

artículo científico publicado en 2018

Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report

scientific article published on 21 September 2020

Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity

article

Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome.

artículo científico publicado en 2016

Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy

Significant reduction in the visits to the emergency room department during the COVID-19 pandemic in a tertiary hospital in Greece: Indirect victims of the pandemic?

artículo científico publicado en 2020

TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma

artículo científico publicado en 2015

The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EP

artículo científico publicado en 2013

The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma

scientific article published on 25 September 2020

The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents

artículo científico publicado en 2017

The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group

scholarly article by Evangelos Terpos et al published 15 October 2013 in American Journal of Hematology

The synergistic effect of panobinostat (LBH589) with melphalan or doxorubicin on multiple myeloma cells; rationale for the use of combination regimens in myeloma patients ⬇️

artículo científico publicado el 19 de noviembre de 2010

Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents

article

Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis

artículo científico publicado en 2020

Tobacco smoking and risk of multiple myeloma: A meta-analysis of 40 observational studies

article

Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop

artículo científico publicado en 2019

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone

artículo científico publicado en 2007

Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens

artículo científico publicado en 2008

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus

artículo científico publicado en 2014

Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)

artículo científico publicado en 2010

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda